Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HIV-associated multicentric Castleman disease

HIV-associated multicentric Castleman disease Eric Oksenhendler Department of Clinical Immunology, Hoˆpital Purpose of review Saint-Louis, Paris, France In this review we will discuss the recent findings in HIV-associated multicentric Correspondence to Eric Oksenhendler, Department of Castleman disease. On the basis of current knowledge on pathophysiology, we will Clinical Immunology, Hoˆpital Saint-Louis, 1 Avenue illustrate different therapeutic approaches and try to provide guidelines at least for the Claude Vellefaux, 75010 Paris, France Tel: +33 1 42 49 96 90; fax: +33 1 42 49 94 72; initial care of the disease. e-mail: eric.oksenhendler@sls.aphp.fr Recent findings Current Opinion in HIV and AIDS 2009, On the basis of pathological and virological data, pathophysiology appears to conjugate 4:16–21 both proliferation of human herpesvirus (HHV-8) infected plasmablasts and replication of HHV-8. Therefore, recent therapies have targeted the infected cells using chemotherapy or rituximab, an anti-CD20 monoclonal antibody or both, and the virus replication by using valganciclovir, a potent antiviral drug usually used against cytomegalovirus. Summary Etoposide is the most effective first-line therapy for active multicentric Castleman disease. Rituximab can be used after an initial control of the attack and provides a 1-year remission rate above 70%. Exacerbation of Kaposi sarcoma lesions, observed in half of the patients with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

HIV-associated multicentric Castleman disease

Current Opinion in HIV and Aids , Volume 4 (1) – Jan 1, 2009

Loading next page...
 
/lp/wolters-kluwer-health/hiv-associated-multicentric-castleman-disease-N9BDD6FziR

References (128)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e328319bca9
Publisher site
See Article on Publisher Site

Abstract

Eric Oksenhendler Department of Clinical Immunology, Hoˆpital Purpose of review Saint-Louis, Paris, France In this review we will discuss the recent findings in HIV-associated multicentric Correspondence to Eric Oksenhendler, Department of Castleman disease. On the basis of current knowledge on pathophysiology, we will Clinical Immunology, Hoˆpital Saint-Louis, 1 Avenue illustrate different therapeutic approaches and try to provide guidelines at least for the Claude Vellefaux, 75010 Paris, France Tel: +33 1 42 49 96 90; fax: +33 1 42 49 94 72; initial care of the disease. e-mail: eric.oksenhendler@sls.aphp.fr Recent findings Current Opinion in HIV and AIDS 2009, On the basis of pathological and virological data, pathophysiology appears to conjugate 4:16–21 both proliferation of human herpesvirus (HHV-8) infected plasmablasts and replication of HHV-8. Therefore, recent therapies have targeted the infected cells using chemotherapy or rituximab, an anti-CD20 monoclonal antibody or both, and the virus replication by using valganciclovir, a potent antiviral drug usually used against cytomegalovirus. Summary Etoposide is the most effective first-line therapy for active multicentric Castleman disease. Rituximab can be used after an initial control of the attack and provides a 1-year remission rate above 70%. Exacerbation of Kaposi sarcoma lesions, observed in half of the patients with

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Jan 1, 2009

There are no references for this article.